Clinical Trials

Enrolling Trials

41-50  of  147
pCIRB, The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Brandt, Jon
Biology
Child
This phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with or without Down syndrome and newly diagnosed, standard risk B-lymphoblastic leukemia or B-lymphoblastic lymphoma. Monoclonal antibodies, such as blinatumomab, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as vincristine, dexamethasone, prednisone, prednisolone, pegaspargase, methotrexate, cytarabine, mercaptopurine, doxorubicin, cyclophosphamide, and thioguanine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Leucovorin decreases the toxic effects of methotrexate. Giving monoclonal antibody therapy with chemotherapy may kill more cancer cells. Giving blinatumomab and combination chemotherapy may work better then combination chemotherapy alone in treating patients with B-ALL. This trial also assigns patients into different chemotherapy treatment regimens based on risk (the chance of cancer returning after treatment). Treating patients with chemotherapy based on risk may help doctors decide which patients can best benefit from which chemotherapy treatment regimens.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
pCIRB, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
Brandt, Jon
Mutations
Child
This phase II trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back or do not respond to treatment and have spread to other places in the body. Ensartinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
pCIRB, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Brandt, Jon
Mutations
Mutations
Adult, Child
This phase II trial studies how well vismodegib and focal adhesion kinase (FAK) inhibitor GSK2256098 work in treating patients with meningiomas that may have gotten bigger or grew back after treatment. Vismodegib and FAK inhibitor GSK2256098 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
pCIRB, Renal Tumors Classification, Biology, and Banking Study
Brandt, Jon
Biology
Child
This phase II/III trial compares the effect of the combination of high-dose cisplatin every three weeks and radiation therapy versus low-dose cisplatin weekly and radiation therapy for the treatment of patients with locoregionally advanced head and neck cancer. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. This study is being done to find out if low-dose cisplatin given weekly together with radiation therapy is the same or better than high-dose cisplatin given every 3 weeks together with radiation therapy in treating patients with head and neck cancer.
Marshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI 54449
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
pCIRB, Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Brandt, Jon
Kidney Tumors
Child
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT)and regimen ICE/Cyclo/Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial WT).
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
pCIRB; A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin
Brandt, Jon
Rhabdomyosarcoma/Soft Tissue Sarcoma
Child
This phase III trial compares the effect of vinorelbine with vincristine, dactinomycin, and cyclophosphamide (VAC) followed by vinorelbine and cyclophosphamide versus VAC followed by vinorelbine and cyclophosphamide for the treatment of high risk rhabdomyosarcoma. Chemotherapy drugs, such as vinorelbine, vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vinorelbine and VAC may kill more tumor cells. Adding maintenance therapy (vinorelbine and cyclophosphamide) after VAC therapy, with or without vinorelbine, may help get rid of the cancer and/or lower the chance that the cancer comes back.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
pCIRB, A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma.
Brandt, Jon
Rhabdomyosarcoma/Soft Tissue Sarcoma
Child
This phase III trial compares the effect of vincristine, dactinomycin, and cyclophosphamide to vincristine and dactinomycin in treating patients with very low risk or low risk fusion negative rhabdomyosarcoma and examines the use of molecular risk stratification in the treatment of rhabdomyosarcoma. Patients with certain tumor mutations will be treated with longer therapy. Giving standard chemotherapy drugs for a longer time may work better in treating patients with rhabdomyosarcoma with mutations. Chemotherapy drugs, such as vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues of the body.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
WCG, DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)
Sharma, Rohit
Melanoma
Adult
Determine the association of GEP test result with SLNB surgical decisions in patients with SLNB-eligible T1-T2 melanoma Track and evaluate 5-year clinical outcomes for patients in each GEP subclass, including those who did and did not undergo SLNB and those with T3-T4 melanoma
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - River Region at Stevens Point
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
ICH, CIRB, Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Ly, Bevan
Breast
Adult
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
SIRB, A Window to Future Outcomes of Antihypertensive Therapy and Superimposed Preeclampsia for Mothers with Mild Chronic Hypertension Maternal Follow-Up
Hashimoto, Kazumasa
Obstetrics & Gynecology
Adult
VHIRB-The Chronic Hypertension and Pregnancy (CHAP) Project randomized pregnant women with mild chronic hypertension (CHTN) to usual care (i.e. antihypertensive therapy only if the patient experienced severe hypertension defined as systolic blood pressure (SBP) =160 mmHg or diastolic blood pressure (DBP) =105 mmHg) or to intervention (i.e. antihypertensive therapy to goal BP < 140/90 mmHg).
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449